Findings suggest that a majority of profits from prescription drug sales are going to supply chain entities and discounts.
Since the beginning of January, more than 63,000 individuals chose marketplace health plans.
Humira is currently approved to treat rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Changing warfarin management may prevent patients from receiving too much or too little of the drug.
Children born to mothers who took heartburn medication were more likely to visit the physician for asthma symptoms.
Majority of patients do not adhere to dietary guidelines set by the US Department of Agriculture.
Top news of the day from across the healthcare landscape.
View More >
Trulance (plecanatide) is a once-daily oral treatment for chronic idiopathic constipation in adult patients.
From the Journals
A new ophthalmic formulation of bimatoprost was found to improve adherence and persistence compared with the original formulation of bimatoprost.
Although naloxone delivery devices are proven to reduce opioid overdoses, challenges persist in increasing the use of these devices in the community setting.
The involvement of community pharmacists is vital to reduce prescription drug abuse through the use of Electronic Prescription Drug Monitoring Programs.
Benefit structure and formulary design characteristics are important for individuals with high out-of-pocket costs in federally facilitated Health Insurance Exchanges.
A state-of-the-art predictive analysis tool that finds patients with rare diseases in a complex database could be valuable to stakeholders, who would achieve savings by helping physicians prescribe the appropriate treatment sooner.
A model of formulary decision making that evaluates medications based on usage could have significant implications for providers, consumers, and manufacturers.
This study explores the impact of a Medicare Part D formulary tier change, specifically with respect to branded insulin products, on insulin adherence, hemoglobin A1C, and diabetes-related events in elderly diabetic beneficiaries strategies for selection of appropriate and cost-effective therapy will also be discussed.